2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Cytochrome P450

Cytochrome P450

CYPs

Cytochrome P450

Related Products

PDF 2.8 MB

Cytochrome p450 comprises a superfamily of heme-thiolate proteins named for the spectral absorbance peak of their carbon-monoxide-bound species at 450 nm. Having been found in every class of organism, including Archaea, the p450 superfamily is believed to have originated from an ancestral gene that existed over 3 billion years ago. Repeated gene duplications have subsequently given rise to one of the largest of multigene families. These enzymes are notable both for the diversity of reactions that they catalyze and the range of chemically dissimilar substrates upon which they act. Cytochrome p450s support the oxidative, peroxidative and reductive metabolism of such endogenous and xenobiotic substrates as environmental pollutants, agrochemicals, plant allelochemicals, steroids, prostaglandins and fatty acids. In humans, Cytochrome p450s are best known for their central role in phase I drug metabolism where they are of critical importance to two of the most significant problems in clinical pharmacology: drug interactions and interindividual variability in drug metabolism.

Cytochrome P450 Isoform Specific Products:

Cytochrome P450 Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B1751E
    Quinidine polygalacturonate
    		Inhibitor
    Quinidine polygalacturonate is an antiarrhythmic agent. Quinidine polygalacturonate is a potent, orally active, selective cytochrome P450db inhibitor. Quinidine polygalacturonate is also a K+ channel blocker with an IC50 of 19.9 μM, and can induce apoptosis. Quinidine polygalacturonate can be used for malaria research.
    Quinidine polygalacturonate
  • HY-G0024A
    Vildagliptin carboxylic acid metabolite TFA
    		Inhibitor
    Vildagliptin carboxylic acid metabolite (M20.7) TFA is a potent P450 enzyme activity inhibitor.
    Vildagliptin carboxylic acid metabolite TFA
  • HY-14225
    BMS-764459
    		Inducer
    BMS-764459 is a CRF1 antagonist. BMS-764459 can be used for the research of neurological disorders such as depression and anxiety. BMS-764459 is also an atypical CYP1A1 inducer.
    BMS-764459
  • HY-164457
    ASN-001
    		Inhibitor
    ASN-001 is an orally active CYP-17A1 lyase inhibitor that selectively inhibits testosterone synthesis. ASN-001 has anticancer activity and can be used for research in the field of prostate cancer.
    ASN-001
  • HY-172783
    Aromatase-IN-5
    		Inhibitor
    Aromatase-IN-5 (Compound 10) is a potent inhibitor of aromatase with an IC50 value of 0.06 μM. Aromatase-IN-5 effectively blocks estrogen production. Aromatase-IN-5 inhibits the proliferation of breast cancer cell lines like MCF-7, arrests the cell cycle at the G1 phase, and induces apoptosis. Aromatase-IN-5 is promising for research of breast cancer.
    Aromatase-IN-5
  • HY-174973
    CYP51-IN-26
    		Inhibitor
    CYP51-IN-26 is a CYP51 inhibitor with an IC50 value of approximately 0.40 μM. CYP51-IN-26 eradicates C. auris biofilms. CYP51-IN-26 demonstrates significantly improved intracellular uptake in an accumulation assay. CYP51-IN-26 protects against C. auris infection in both G. mellonella and D. melanogaster models. CYP51-IN-26 can be used for research on fungal infections.
    CYP51-IN-26
  • HY-90010R
    Tolterodine tartrate (Standard)
    		Substrate
    Tolterodine (tartrate) (Standard) is the analytical standard of Tolterodine tartrate. This product is intended for research and analytical applications. Tolterodine ((R)-(+)-Tolterodine) is a mAChR inhibitor and substrate for cytochrome P450 enzymes. Tolterodine competitively binds acetylcholine, reduces sympathetic excitation, and inhibits involuntary bladder muscle contraction. Tolterodine restores the Nrf2/NF-κB signaling pathway, mediates protection against inflammatory response and ferroptosis. Tolterodine ameliorates LPS (HY-D1056)-induced reactive oxygen species production and lipid oxidation. Tolterodine can be used for the research of urinary tract infections and overactive bladder.
    Tolterodine tartrate (Standard)
  • HY-163571
    CYP51-IN-17
    		Inhibitor
    CYP51-IN-17 (compound 7a) is a potent CYP51 inhibitor with an IC50 of 0.377 μg/mL. CYP51-IN-17 shows significant fungicidal activity against B. cinerea with an EC50 of 0.326 μg/mL.
    CYP51-IN-17
  • HY-119996
    AR-C141990
    		Inhibitor
    AR-C141990 (Compound 30) is a potent blocker of the monocarboxylate transporter MCT1 with a Ki of 4.8 nM. AR-C141990 (Compound 30) inhibits CYP3A4 and CYP2C9 with IC50 values of 16 μM.
    AR-C141990
  • HY-181235
    COX-2/Aromatase-IN-1
    		Inhibitor
    COX-2/Aromatase-IN-1 is a potent dual inhibitor of COX-2 and aromatase. COX-2/Aromatase-IN-1 can simultaneously inhibit COX-2 and aromatase, significantly suppress inflammation and induce proliferation inhibition of breast cancer cells. COX-2/Aromatase-IN-1 exerts anti-breast cancer and anti-inflammatory effects in the MCF-7 breast cancer cell and carrageenan-induced rat paw edema model. COX-2/Aromatase-IN-1 can be used for the study of inflammation and breast cancer.
    COX-2/Aromatase-IN-1
  • HY-151119
    Anticancer agent 78
    		Inhibitor
    Anticancer agent 78 is a potent anticancer agent. Anticancer agent 78 shows cytotoxicity. Anticancer agent 78 exhibits anti-aromatase activity with an IC50 value of 0.9 µM. Anticancer agent 78 has the potential for the research of breast cancer.
    Anticancer agent 78
  • HY-70006A
    Galeterone hydrochloride
    		Inhibitor
    Galeterone (TOK-001) hydrochloride is a potent, orally active molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2. Galeterone hydrochloride also functions as a CYP17 inhibitor (IC50 = 47 nM). Galeterone hydrochloride induces cell apoptosis. Galeterone hydrochloride inhibits tumor growth in human prostate cancer xenograft mouse models. Galeterone hydrochloride can be used for castration resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC) research[1][2].
    Galeterone hydrochloride
  • HY-150574
    CYP3A4-IN-1
    		Inhibitor
    CYP3A4-IN-1 (compound 5a) is a potent cytochrome P450 3A4 (CYP3A4) inhibitor with an IC50 value of 0.085 µM.
    CYP3A4-IN-1
  • HY-144643
    CYP51/HDAC-IN-1
    		Inhibitor
    CYP51/HDAC-IN-1 is a potent, orally active CYP51/HDAC dual inhibitor. CYP51/HDAC-IN-1 inhibits important virulence factors and down-regulated resistance-associated genes. CYP51/HDAC-IN-1 exhibits potent therapeutic effects for both tropical candidiasis and cryptococcal meningitis.
    CYP51/HDAC-IN-1
  • HY-122410R
    Dihydrolanosterol (Standard)
    Citraconic acid (Standard) is the analytical standard of Citraconic acid. This product is intended for research and analytical applications. Citraconic acid belongs to the class of organic compounds known as methyl-branched fatty acids.
    Dihydrolanosterol (Standard)
  • HY-181163
    Caspase-3/7 activator 4
    		Inhibitor
    Caspase-3/7 activator 4 is a caspase-3 activator and caspase-7 activator. Caspase-3/7 activator 4 inhibits key enzymes in estrogen biosynthesis, including aromatase (IC50 = 38.3 nM) and steroid sulfatase (IC50 = 12.7 µM), and selectively suppresses COX-2 (IC50 = 5.38 µM). Caspase-3/7 activator 4 shows strong antioxidant activity (DPPH: IC50 = 16.26 µM). Caspase-3/7 activator 4 inhibits estrogen synthesis, suppresses estrogen availability, reduces prostaglandin production, increases caspase-3/7 expression, induces G0/G1 cell cycle arrest, induces apoptotic cell death, reduces circulating TNF-α and VEGFR-II levels, restores hepatorenal function markers and histoarchitecture, restores antioxidant defense enzyme activity, reduces lipid peroxidation, exerts antiproliferative activity against breast cancer cells, exerts antitumor activity in the Ehrlich ascites carcinoma models. Caspase-3/7 activator 4 can be used for the research of breast cancer, ehrlich ascites carcinoma.
    Caspase-3/7 activator 4
  • HY-N2689
    (R)-6',7'-Dihydroxybergamottin
    		Inhibitor
    (R)-6',7'-Dihydroxybergamottin ((R)-6′,7′-DHB) is a competitive inhibitor of human and rat CYP1A1 activity with Kis of 55 μM and 1.72 μM, respectively. (R)-6',7'-Dihydroxybergamottin has the potential for cancer research.
    (R)-6',7'-Dihydroxybergamottin
  • HY-B0113S1
    Omeprazole-d3-1
    Omeprazole-d3-1 is the deuterium labeled Omeprazole. Omeprazole-1 (H 16868) is an orally active H+,K+-ATPase inhibitor and a proton pump inhibitor. Omeprazole-1 competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole-1 inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole-1 inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole-1 alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole-1 aslo has neuroprotective and antibacterial effects.
    Omeprazole-d<sub>3</sub>-1
  • HY-N10191
    Hydroaurantiogliocladin
    Hydroaurantiogliocladin is a quinol. Hydroaurantiogliocladin can be used as substrate for the quinol-cytochrome c oxidoreductase activity (beef heart enzyme).
    Hydroaurantiogliocladin
  • HY-N0693R
    Schisandrin A (Standard)
    		Inhibitor
    Schisandrin A (Standard) is the analytical standard of Schisandrin A. This product is intended for research and analytical applications. Schisandrin A inhibits CYP3A activity with an IC50 of 6.60 μM and Ki of 5.83 μM, respectively.
    Schisandrin A (Standard)
Cat. No. Product Name / Synonyms Application Reactivity
Cytochrome P450 Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.